Fulgent GeneticsFLGT +0.81%59 PB Ratio is 0.53 as of Jun. 25, 2026, which is 61% below its 10-year median of 1.35. GuruFocus rates FLGT with a GF Score™ of 59/100 and a GF Value™ of $23.98 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 196 Medical Diagnostics & Research companies, Fulgent Genetics ranks better than 91.33% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), Fulgent Genetics's share price is $19.285. Fulgent Genetics's Book Value per Share for the quarter that ended in Mar. 2026 was $36.39. Hence, Fulgent Genetics's PB Ratio of today is 0.53.
The historical rank and industry rank for Fulgent Genetics's PB Ratio or its related term are showing as below:
FLGT'
s PB Ratio Range Over the Past 10 Years
Min: 0.39 Med: 1.35 Max: 12.03
Current: 0.53
During the past 12 years, Fulgent Genetics's highest PB Ratio was 12.03. The lowest was 0.39. And the median was 1.35.
FLGT's PB Ratio is ranked better than 91.33% of 196
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.05
vs FLGT: 0.53
During the past 12 months, Fulgent Genetics's average Book Value Per Share Growth Rate was -1.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -6.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 7.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 56.50% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Fulgent Genetics was 139.00% per year. The lowest was -6.00% per year. And the median was 55.95% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Fulgent Genetics PB Ratio Related Terms
Fulgent Genetics PB Ratio Historical Data
* Premium members only.
The historical data trend for Fulgent Genetics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Fulgent Genetics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fulgent Genetics PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Fulgent Genetics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Fulgent Genetics (FLGT) has a PB Ratio of 0.53 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Fulgent Genetics and its competitors. This is 61% below median its historical median of 1.35. Over the past decade, Fulgent Genetics' PB Ratio has ranged from 0.39 to 12.03. According to the industry distribution chart, Fulgent Genetics ranks #17 out of 196 companies in the Medical Diagnostics & Research industry, placing it in the top 8.7%.
Is Fulgent Genetics' PB Ratio too high?
Fulgent Genetics' current PB Ratio of 0.53 is 61% below median its 10-year median of 1.35. Over the past 10 years, this metric has ranged from a low of 0.39 to a high of 12.03. The Medical Diagnostics & Research industry median PB Ratio is 2.05. Fulgent Genetics' value of 0.53 is 74.1% below this industry median. Based on the distribution chart, Fulgent Genetics ranks #17 out of 196 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Fulgent Genetics has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fulgent Genetics' PB Ratio compare to CSTL and MYGN?
According to the Medical Diagnostics & Research industry distribution chart, Fulgent Genetics ranks #17 out of 196 companies for PB Ratio. This places Fulgent Genetics in the top 9% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.05. Fulgent Genetics' value of 0.53 is 74.1% below this benchmark. Historically, Fulgent Genetics' own PB Ratio has ranged from 0.39 to 12.03 over the past decade. While the company's 10-year median is 1.35 vs. the industry median of 2.05, Fulgent Genetics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.05, based on 196 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fulgent Genetics's current PB Ratio of 0.53 is 74.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Fulgent Genetics and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fulgent Genetics's current PB Ratio is 0.53, which is 61% below median its own 10-year median of 1.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulgent Genetics stock overvalued right now?
Based on GuruFocus' analysis, Fulgent Genetics (FLGT) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.98, compared to a current price of $19.29 — trading 19.6% below its estimated fair value. The current PB Ratio is 0.53, which is 61% below median its 10-year median of 1.35 and 74.1% below the Medical Diagnostics & Research industry median of 2.05. Fulgent Genetics' overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Fulgent Genetics (FLGT), the current PB Ratio is 0.53 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fulgent Genetics (FLGT) Overvalued in 2026?
Based on GuruFocus' analysis, Fulgent Genetics stock appears to be undervalued.
The current stock price of $19.29 is trading 19.6% below its estimated GF Value™ of $23.98.
GuruFocus considers Fulgent Genetics to be Modestly Undervalued.
Key valuation signals for FLGT:
PB Ratio: 0.53 (61% below median its 10-year median of 1.35)
GF Value™: $23.98 vs. price of $19.29 (19.6% below fair value)
Industry Position: 74.1% below the Medical Diagnostics & Research median (#17 of 196)
No single metric tells the full story. See the FLGT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
59GF Score
Get the complete analysis for FLGT
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FLGT has been successfully added to your 
